At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma ...
Remynd NV is back on track with its novel septin-targeting Alzheimer’s disease program after addressing liver toxicity ...
At the International Myeloma Society meeting, Brightpath Biotherapeutics Co. Ltd. presented data for BP-2202, an ...
The value of biopharma deals has generally trended upward, despite year-over-year and month-to-month volatility. BioWorld’s ...
New collaborations involving Henlius, Amberstone, Sanyou Bio and Novocodex highlight efforts to improve the safety, precision ...
Acadia Pharmaceuticals Inc.’s near miss disclosed Sept. 24 in phase II with 5HT2A receptor inverse agonist remlifanserin in ...
Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small ...
Eli Lilly and Co. has struck another major China partnership, signing a discovery-stage collaboration with Beijing-based ...
Sotio Biotech AS’s SOT-106 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcoma and ...
Cellular senescence is commonly associated with aging, but it also plays essential roles during embryonic development.
Xtalpi Inc. has submitted an IND application to the FDA for KQTD-126, a gut-restricted pan-TRK inhibitor designed to treat chronic intestinal pain associated with irritable bowel syndrome and ...
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has presented new dual contrast gadolinium compounds acting as magnetic resonance and fluorescence imaging agents potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results